Advertisement

Journal of Cancer Research and Clinical Oncology

, Volume 144, Issue 8, pp 1569–1580 | Cite as

The value of EBV DNA in early detection of post-transplant lymphoproliferative disorders among solid organ and hematopoietic stem cell transplant recipients

  • Neval E. Wareham
  • Amanda Mocroft
  • Henrik Sengeløv
  • Caspar Da Cunha-Bang
  • Finn Gustafsson
  • Carsten Heilmann
  • Martin Iversen
  • Nikolai S. Kirkby
  • Allan Rasmussen
  • Søren Schwartz Sørensen
  • Jens D. Lundgren
  • MATCH in PERSIMUNE study group
Original Article – Clinical Oncology
  • 142 Downloads

Abstract

Purpose

Emerging EBV DNAemia in plasma is considered an early sign of post-transplant lymphoproliferative disorder (PTLD). The aim of this study was to quantify the extent of benefit from screening for EBV DNAemia to detect emerging PTLD among solid organ (SOT) or hematopoietic stem cell transplant recipients (HSCT).

Methods

We used receiver operating characteristic (ROC) curves for assessing ability of models to predict PTLD. Among 2642 recipients transplanted between January 2004 and December 2014, 79 (3%) developed PTLD.

Results

EBV DNAemia was observed in 331/1784 recipients (18.6%, 95% CI 16.8–20.4) with measured EBV DNA. The area under the curve (AUC) of the ROC of EBV DNAemia to identify persons with subsequent PTLD was 72% (95% CI, 64–79%) among SOT and 59% (51–68%) among HSCT. Including clinical predictors such as age, gender, transplant year and type, high-risk EBV serostatus, and routine biochemistry in addition to EBV DNAemia increased AUC to 83% (75–90%) among SOT and 84% (79–89%) among HSCT. Among HSCT, including additional factors such as T-cell-depleting treatment, acute graft vs. host disease and donor match increased AUC to 85% (78–91%).

Conclusions

We constructed a model to better predict PTLD compared to EBV DNA screening alone which could have clinical implications.

Keywords

Transplantation EBV DNA PTLD AUROC 

Notes

Author contributions

NEW designed the study, assisted in data collection and analysis, and drafted and edited the manuscript. JDL designed the study, assisted in data collection and analysis, and edited the manuscript. AM designed the study, performed data analysis and edited the manuscript. CDB, NK, FG, MI, AR, HS, SSS, and CH assisted in data collection and edited the manuscript.

Funding

This work was supported by Danish National Research Foundation [Grant number 126].

Compliance with ethical standards

Conflict of interest

NEW declares that she has no conflict of interest. AM declares that she has no conflict of interest. CDB declares that he has no conflict of interest. NK declares that he has no conflict of interest. FG declares that he has no conflict of interest. CH declares that he has no conflict of interest. MI declares that he has no conflict of interest. AR declares that he has no conflict of interest. HS declares that he has no conflict of interest. SSS declares that he has no conflict of interest. JDL declares that he has no conflict of interest.

Ethical approval

All procedures performed in studies involving human participants were in accordance with the ethical standards of the institutional and/or national research committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.

Informed consent

All relevant approval for this project was obtained from the Danish Health and Medicines Authorities according to Danish legislation on retrospective studies. For this type of study, formal consent is not required.

Data availability

The datasets generated during and/or analyzed during the current study are available from the corresponding author on reasonable request.

Supplementary material

432_2018_2674_MOESM1_ESM.docx (17 kb)
Additional Supporting Information may be found online in the supporting information tab for this article. Supporting information include definition of PTLD (Online Resource 1). (DOCX 17 KB)

References

  1. Bamoulid J, Courivaud C, Coaquette A et al (2013) Subclinical Epstein–Barr virus viremia among adult renal transplant recipients: incidence and consequences. Am J Transplant 13(3):656–662CrossRefPubMedGoogle Scholar
  2. Dharnidharka VR (2017) Peripheral blood Epstein–Barr viral nucleic acid surveillance as a marker for posttransplant cancer risk. Am J Transplant 17(3):611–616CrossRefPubMedGoogle Scholar
  3. Ekenberg C, Lodding IP, Wareham NE et al (2017) Risk of infectious diseases among first-degree relatives of transplant recipients who develop CMV infection: is the infectious phenotype inheritable? Eur J Clin Microbiol Infect Dis 36:2391–2398CrossRefPubMedGoogle Scholar
  4. Fox CP, Burns D, Parker AN et al (2014) EBV-associated post-transplant lymphoproliferative disorder following in vivo T-cell-depleted allogeneic transplantation: clinical features, viral load correlates and prognostic factors in the rituximab era. Bone Marrow Transplant 49(2):280–286CrossRefPubMedGoogle Scholar
  5. Green M, Michaels MG (2013) Epstein–Barr virus infection and posttransplant lymphoproliferative disorder. Am J Transplant 13(Suppl 3):41–54CrossRefPubMedGoogle Scholar
  6. Hocker B, Fickenscher H, Delecluse HJ et al (2013) Epidemiology and morbidity of Epstein–Barr virus infection in pediatric renal transplant recipients: a multicenter, prospective study. Clin Infect Dis 56(1):84–92CrossRefPubMedGoogle Scholar
  7. Holman CJ, Karger AB, Mullan BD, Brundage RC, Balfour HH Jr (2012) Quantitative Epstein–Barr virus shedding and its correlation with the risk of post-transplant lymphoproliferative disorder. Clin Transplant 26(5):741–747CrossRefPubMedPubMedCentralGoogle Scholar
  8. Landgren O, Gilbert ES, Rizzo JD et al (2009) Risk factors for lymphoproliferative disorders after allogeneic hematopoietic cell transplantation. Blood 113(20):4992–5001CrossRefPubMedPubMedCentralGoogle Scholar
  9. Lodding IP, Sengelov H, da Cunha-Bang C et al (2015) Clinical application of variation in replication kinetics during episodes of post-transplant cytomegalovirus infections. EBioMedicine 2(7):699–705CrossRefPubMedPubMedCentralGoogle Scholar
  10. Martinez OM, Krams SM (2017) The immune response to Epstein–Barr virus and implications for posttransplant lymphoproliferative disorder. Transplantation 101(9):2009–2016CrossRefPubMedGoogle Scholar
  11. Meijer E, Slaper-Cortenbach IC, Thijsen SF, Dekker AW, Verdonck LF (2002) Increased incidence of EBV-associated lymphoproliferative disorders after allogeneic stem cell transplantation from matched unrelated donors due to a change of T cell depletion technique. Bone Marrow Transplant 29(4):335–339CrossRefPubMedGoogle Scholar
  12. Morton M, Coupes B, Roberts SA et al (2014) Epstein–Barr virus infection in adult renal transplant recipients. Am J Transplant 14(7):1619–1629CrossRefPubMedGoogle Scholar
  13. Nijland ML, Kersten MJ, Pals ST, Bemelman FJ, Ten Berge IJ (2016) Epstein–Barr virus-positive posttransplant lymphoproliferative disease after solid organ transplantation: pathogenesis, clinical manifestations, diagnosis, and management. Transplant Direct 2(1):e48CrossRefPubMedGoogle Scholar
  14. Ok CY, Li L, Young KH (2015) EBV-driven B-cell lymphoproliferative disorders: from biology, classification and differential diagnosis to clinical management. Exp Mol Med 47:e132CrossRefPubMedPubMedCentralGoogle Scholar
  15. Parker A, Bowles K, Bradley JA et al (2010) Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients—BCSH and BTS guidelines. Br J Haematol 149(5):675–692CrossRefPubMedGoogle Scholar
  16. Patriarca F, Medeot M, Isola M et al (2013) Prognostic factors and outcome of Epstein–Barr virus DNAemia in high-risk recipients of allogeneic stem cell transplantation treated with preemptive rituximab. Transpl Infect Dis 15(3):259–267CrossRefPubMedGoogle Scholar
  17. Sabattini E, Bacci F, Sagramoso C, Pileri SA (2010) WHO classification of tumours of haematopoietic and lymphoid tissues in 2008: an overview. Pathologica 102(3):83–87PubMedGoogle Scholar
  18. San-Juan R, Manuel O, Hirsch HH et al (2015) Current preventive strategies and management of Epstein–Barr virus-related post-transplant lymphoproliferative disease in solid organ transplantation in Europe. Results of the ESGICH Questionnaire-based cross-sectional survey. Clin Microbiol Infect 21(6):604–609CrossRefPubMedGoogle Scholar
  19. Schaffer K, Hassan J, Staines A et al (2011) Surveillance of Epstein–Barr virus loads in adult liver transplantation: associations with age, sex, posttransplant times, and transplant indications. Liver Transpl 17(12):1420–1426CrossRefPubMedGoogle Scholar
  20. Styczynski J, Reusser P, Einsele H et al (2009) Management of HSV, VZV and EBV infections in patients with hematological malignancies and after SCT: guidelines from the Second European Conference on Infections in Leukemia. Bone Marrow Transplant 43(10):757–770CrossRefGoogle Scholar
  21. Styczynski J, Gil L, Tridello G et al (2013) Response to rituximab-based therapy and risk factor analysis in Epstein–Barr virus-related lymphoproliferative disorder after hematopoietic stem cell transplant in children and adults: a study from the Infectious Diseases Working Party of the European Group for Blood and Marrow Transplantation. Clin Infect Dis 57(6):794–802CrossRefPubMedGoogle Scholar
  22. Uhlin M, Wikell H, Sundin M et al (2014) Risk factors for Epstein–Barr virus-related post-transplant lymphoproliferative disease after allogeneic hematopoietic stem cell transplantation. Haematologica 99(2):346–352CrossRefPubMedPubMedCentralGoogle Scholar
  23. van Esser JW, van der Holt B, Meijer E et al (2001) Epstein–Barr virus (EBV) reactivation is a frequent event after allogeneic stem cell transplantation (SCT) and quantitatively predicts EBV-lymphoproliferative disease following T-cell—depleted SCT. Blood 98(4):972–978CrossRefPubMedGoogle Scholar
  24. Wagner HJ, Cheng YC, Huls MH et al (2004) Prompt versus preemptive intervention for EBV lymphoproliferative disease. Blood 103(10):3979–3981CrossRefPubMedGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2018

Authors and Affiliations

  • Neval E. Wareham
    • 1
  • Amanda Mocroft
    • 2
  • Henrik Sengeløv
    • 3
  • Caspar Da Cunha-Bang
    • 3
  • Finn Gustafsson
    • 4
  • Carsten Heilmann
    • 5
  • Martin Iversen
    • 4
  • Nikolai S. Kirkby
    • 6
  • Allan Rasmussen
    • 7
  • Søren Schwartz Sørensen
    • 8
  • Jens D. Lundgren
    • 1
  • MATCH in PERSIMUNE study group
  1. 1.CHIP, Department of Infectious Diseases, Section 2100Rigshospitalet, University of CopenhagenCopenhagen ØDenmark
  2. 2.Centre for Clinical Research, Epidemiology, Modelling and Evaluation (CREME), Institute for Global healthUniversity College LondonLondonUK
  3. 3.Department of HaematologyRigshospitaletCopenhagenDenmark
  4. 4.Department of CardiologyRigshospitaletCopenhagenDenmark
  5. 5.Department of PediatricsRigshospitaletCopenhagenDenmark
  6. 6.Department of Clinical MicrobiologyRigshospitaletCopenhagenDenmark
  7. 7.Department of Surgical GastroenterologyRigshospitaletCopenhagenDenmark
  8. 8.Department of NephrologyRigshospitaletCopenhagenDenmark

Personalised recommendations